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Abstract
Background: Dementia is a disabling syndrome, which generally affects aged population more than any other age groups. This syn-
drome has a growing prevalence and incidence worldwide. The prevalence and burden of this group of diseases in Iran have not been 
estimated in a community-based study yet. This paper aims to explain the systematic approach, data sources, research methodology, and 
statistical analysis that will be used to quantify the prevalence and burden of dementia at national and sub-national levels.
Methods: This is the protocol of a secondary data study that explains the design and method of conducting the study. We will use sev-
eral sources of data that will include a systematic review of articles and gray literature which have reported the prevalence or incidence 
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
year at provincial levels, as well as data extracted from 23 million health insurance prescriptions over 8 years and some data from medical 
??????????????????????????? ???????????????????????????????????????????????????????????????????????????????????????????????????????????
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ing plasma glucose, and systolic and diastolic blood pressure at provincial levels which will be used in our models. Two statistical models, 
namely spatio-temporal and hierarchical autoregressive models, will be used for interpolation and extrapolation of missing data.
Conclusion: It seems that the study of national and subnational burden of dementia could provide more accurate estimation of preva-
lence and burden of dementia in Iran with an acceptable level of uncertainty than the previous studies.
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Introduction
Dementia is a chronic syndrome with a growing burden worldwide. Around the world, about 8.4% of people aged ????????????????????????????????????????????????????????-
mentia rises with aging, so that its prevalence increases globally 
from 1.3% in the age group 60–64 years to 63.9% in the age group 
??????????1 The number of patients with dementia in 2013 was 
estimated at 44.35 million and it will reach 75.62 million in 2030. 
At present, 38% of these patients live in high income countries 
and 62% live in low income countries.2 The Global Burden of 
Diseases, Injuries, and Risk Factors (GBD) study estimated dis-
abitity-adjusted like years (DALYs) of dementia to be 11.349 
(9.147–13.741) million in 2010, which had a growth of 99.3% 
compared with 1990.3 Although it was the cause of only about 
0.46% of the total burden of diseases,3 the economic costs of de-
mentia were approximately 604 billion dollars in 2010 which 
were similar to the costs of cardiovascular diseases and cancers.4,5
Some studies have indicated huge variability in the prevalence 
and burden of dementia in different regions and countries.1,6,7 At 
???????????????????????????????????????????????????????????????????
the prevalence of risk factors of dementia in various regions and 
countries.8 Taking into consideration the variation in the preva-
lence of most diseases in various regions of the world and also 
the changes in the prevalence of diseases over the time, a periodic 
estimation of the burden of diseases at national and sub-national 
levels is not only reasonable but also necessary for every country. 
This information can help policymakers at the national and re-
gional levels to make better decisions about resource allocation. 
??????????????????????????????????????????????????????????????????
conducted in 2003.9 Because of scarcity of data, these estimations 
of the burden of diseases were with high levels of uncertainty. 
Over the recent 10 years, evidences about the prevalence and in-
?????????????????????????????????????????????????????????????????
quantitative methods have been developed recently, which enable 
researchers to perform more accurate estimations about epidemio-
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logic characteristics of diseases and risk factors. Therefore, con-
ducting a new study about the burden of diseases seems necessary. 
This study will particularly consider detecting inequality between 
regions and provinces in Iran. We expect that our study provides 
essential health intelligence to inform policymakers about the im-
portance of dementia in Iran.
Because of scarcity of the epidemiologic data about demen-
tia in Iran, this paper explains the materials and methods of the 
study that aims to provide a relatively precise estimation of the 
prevalence and burden of dementia at national and sub-national 
levels over 24 years from 1990 to 2013, using a combination of 
data collected from a systematic review of prevalence, and also 
???????????????????????????????????????????????????????????????-
tal inpatient study data, death registry data, and data from Iranian 
Alzheimer’s Association (IAA). 
Materials and Methods
This will be a secondary-data study to estimate the burden of de-
mentia and its time-trends over 24 years from 1990 to 2013 at na-
tional and sub-national levels in Iran. This study will be conducted 
by a technical team, which is one of the national and sub-national 
burden of diseases (NASBOD) technical teams10 in collaboration 
with the core team. The teams will estimate the prevalence and 
burden of 290 diseases and 67 risk factors in Iran. More details 
about the NASBOD technical teams are presented elsewhere.10 
????????????????????????????????????????????????????????????????-
mate the prevalence of dementia by sex and age group at national 
and provincial levels using the data from different sources such 
???????????????????????????????????????????????????????????????-
ances prescription data, data from the hospital inpatient study and 
other sources. In the second phase, we will calculate the burden of 
dementia using the DALYs method. DALY will be calculated as 
the sum of the years of life lost (YLL) due to early mortality in the 
population and the years lost due to disability (YLD). 
Data sources
The most important problem facing us is shortage of data on the 
prevalence and incidence of dementia in Iran. In most population-
based health surveys in Iran, there are no data about the preva-
lence and incidence of dementia. Therefore, we need a compre-
hensive gray literature review for extracting related data, which 
have not been published or even reported.
Systematic review
A systematic review of the prevalence of dementia and its related 
diseases will be carried out. This review will be conducted based on 
a protocol, which is compatible with the NASBOD protocols. The 
international source of search includes the Medline database of the 
National Library of Medicine (PubMed), Web of Science (ISI), Sco-
pus, and Google scholar, as well as three Iranian databases includes 
????????????????????????????????? ????????????????????????????
In addition, gray literatures, including the reports of national and 
sub-national surveys, results of which have not been published as 
articles, and some studies which have not been reported or published 
will be considered. These studies will be found through consultation 
with the experts who work on the dementia domains. 
a. Search strategies
Search strategy will be designed through following guidelines 
provided by experts and also using MeSH-terms and Emtree-
terms. After approving the search strategy by the technical team, it 
will be used for searching international databases. Iranian databas-
es are very sensitive to the spelling of the words used for search, so 
all possible spellings of the words which are equivalent to English 
??????? ????????????????????????????????????????????? ???????? ????
titles, abstracts, and keywords of articles, as well as thesis, disser-
tations, conference proceedings and reports that were published in 
English and/or Persian databases over the mentioned period.
The gray literatures will include reports and booklets of the 
Ministry of Health and Medical Education (MOHME), and the 
Ministry of Cooperatives, Labor, and Social Welfare, which have 
not been published as an article in the databases. This data will be 
found through interviewing and consultations with experts and the 
????????? ???????????????????????????????????
 
b. Study selection criteria
Our study will include those studies, which have been conducted 
during 1990 to 2014 and have reported the epidemiologic char-
acteristics of dementia in Iran such as prevalence or incidence, 
and have used population-based sampling methods. On the other 
hand, only papers or gray literatures will be considered which 
have reported the prevalence or incidence of dementia in a pop-
ulation-based study, such as community-based cross-sectional 
studies, baseline of population-based cohort studies, population-
????????????????????????????????????????????????????????????????????
surveys. Two trained researchers will review the eligible studies 
independently. In case of inconsistency between the reviewers 
about the inclusion of an article, a third reviewer will review the 
????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????
step, again. In case of disagreement between the reviewers, the 
???????????????????????????????????????????????????????????????????
????????????????????????????????????????????? ?????????????????????????
their data will be inadequate, three times correspondence will be 
made with corresponding author with a three-week interval. If we 
will not receive a response after three weeks from the last letter, 
we will exclude the article. In order to assess the sensitivity of the 
searches, the reference list of selected papers will be reviewed for 
the probable titles of articles, which are eligible but not included 
in the list. If the number of papers found will exceed 10%, the 
search protocol will be revised and the search will be conducted 
????????????????????????????????????????????????????????????????????
their quality will be assessed by two independent reviewers using 
a checklist, which is designed based on the NASBOD appraisal 
tool, and disagreement will be settled at a meeting with the pres-
ence of reviewers. This tool has a scoring model and some of its 
items include sampling method, how much the sample is repre-
sentative of the general population, sample size, and how demen-
tia was diagnosed in that study.
c. Data extraction
Data extraction from eligible full-text papers and other gray lit-
eratures will be performed by two reviewers independently using 
an Excel datasheet and inconsistency between the extracted data 
will be resolved by rechecking the data.
d. Types of data
General information: the source of data, including the name of 
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the authors, type of studies, language, place of study, time of data 
collection, time of publication, type of resource (peer-review ar-
ticle, conference proceeding, thesis or dissertation, reports etc.), 
and citation of the resource. 
Methodological data: type of studies (cross-sectional, cohort, 
??????????????????????????????????????????????????????????????????????
age groups, sample size, method of sampling, ascertainment/de-
???????????????????????????? ??????????????????????????????????-
tia, and response rate. 
Data on the prevalence and incidence: the prevalence and incidence 
????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????
separately (this age range is selected because the GBD 2010 study did 
?????????????????????????????????????????????????????? ??????????3 If part 
of data does not exist in the article, we will try to communicate with 
the corresponding author to obtain the required data. 
If we face various tools used in different studies for diagnosis of 
dementia, we will try to crosswalk between them to decrease the 
heterogeneity of the data.
??????????????????????
In a panel with the presence of expert neurologists and psychia-
trists who are familiar with the treatment of dementia and demen-
tia related diseases, the drugs which are prescribed especially for 
treating dementia will be determined. 
???????????????????????????????????
Drug sales data from all Iranian provinces has been collected 
?????? ?????? ??? ?????? ???? ?????????? ???? ?????????????????
drug sales data could provide an estimate about the crude preva-
lence of dementia in a certain province and year. 
b. Insurance prescription date
From about overall 460 million insurance prescriptions over 8 
years (from 2004 to 2011), about 23 million prescriptions were 
selected randomly. The prescriptions that contain at least one de-
????????????????????????????????????????????????????????????????
estimate the proportion of the number of patients with dementia in 
each age-sex group of the total number of patients in a given year 
and province. Furthermore, we can calculate mean doses of each 
???????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????
???????? ???????????????????????????????????
?????????? ?????????????????????????????????????????????????-
sion tree models for labeling of the diagnosis of dementia from 
the insurance prescriptions. Details of these models are described 
elsewhere.11
Hospital inpatient data
Although, patients with dementia are not usually admitted to 
hospital for their disease, the end stage patients or those with com-
plication may be admitted to hospital. The hospital inpatient data 
that has been already collected could be useful, particularly for 
estimation of the prevalence of severe and complicated dementia. 
The protocol of this study is reported elsewhere.12
Data from death registry
Death registry system is a component of vital registration sys-
tem. If death registration is valid, it is the best source of estimation 
??????????????????????????????????????????????????????????????????
similar to other developing countries, is incomplete and entails 
?????????????????13,14???????????????????????????????????????????
is necessary for estimating the premature mortality caused by de-
mentia. This data could help us to estimate the YLD. A group of 
the NASBOD is dealing with the problems of incompleteness and 
??????????????????????????????????????????????????????????????????
and adult mortalities in Iran is explained elsewhere.15,16 
Data of Iranian Alzheimer’s Association (IAA)
The medical records of more than 4000 patients with dementia 
are available in IAA branches. Some of these medical documents 
contain drug adherence rate of patients with dementia. It may help 
us to estimate drug-adherence among Iranian patients with de-
mentia. The data on drug-adherence is applicable for estimation 
of dementia prevalence. 
???? ????????????????????????
???????????????????????????????????????????????????????????????
provinces, we will calculate the DALY of dementia by summing 
up the YLL and YLD.13 
 
???????????????????????????????
We need a matrix of data with 26784 data-cells (36 age-sex 
groups in 31 provinces over 24 years). A likely expected problem 
with this matrix is the presence of several empty cells because 
of shortage of data. Despite our systematic multidimensional ap-
proach for data collection, it is highly probable that the matrix 
suffers a considerable degree of incompleteness. Some covari-
ates at the level of the provinces could be applied to estimate the 
missing data. These covariates include age and sex structure, so-
cioeconomic status, urbanization status, mean years of schooling, 
mean fasting plasma glucose, mean plasma cholesterol, and mean 
systolic and diastolic blood pressure. Other NASBOD groups will 
provide considerable parts of the mentioned data.17 Another prob-
lem with the data is a spatial misalignment of data (i.e., the esti-
mates of Khorasan province before its division into three provinc-
es are not aligned with those estimates of Southern, Northern, and 
Razavi Khorasan after division). Two mathematical approaches, 
naemly multi-level autoregressive and spatio-temporal hierarchi-
cal Bayesian models, will be used to extrapolate and interpolate 
???? ????????? ???????? ??????????????????? ???? ???? ???????????? ???
each year and province through using temporal, juxtaposition and 
covariate data. 
Hierarchical autoregressive multi-level model
In this model, the observed data will be nested in hierarchical 
geographic frameworks, including counties, provinces, sub-re-
gions, regions, and national level. The higher levels lend the infor-
mation to lower levels. This approach will address several other 
components such as linear and nonlinear time trends, mentioned 
covariate effects, nonlinearity in age group prevalence and other 
factors related to heterogeneity of the data sources. More details 
about this model are discussed elsewhere.18 
Spatio-temporal model
The spatio-temporal Bayesian hierarchical models with condi-
tional autoregressive prior for spatial random effects will be util-
ized for estimation of missing values in our study. This modeling 
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strategy assumes that the prevalence of dementia in juxtaposition 
of given region and temporary near the certain time are the proxy 
for estimation of dementia prevalence and its uncertainty in that 
region.19 In addition, an age, sex, time, province missing box could 
borrow information from the nearest temporary and positional 
???????????? ??????????????????????????????? ?????????????????????
also consider the covariate and non-linearity of spatio-temporal 
???????????????????????????????????????????
Discussion
Dementia strains health, social systems, and budgets because of 
severity of disability and long term care that patients with demen-
tia need.4,5 According to the results of the GBD study, the global 
burden of dementia had an increasing trend from 1990 to 2010.3 
It was estimated that this increasing trend will continue and even 
the slope of the trend will rise up to 2050 because of the global 
growing of the aged population proportion.2 It is important that 
the proportion of the population suffering from dementia will in-
crease more quickly in lower income compared to high income 
countries. So, this proportion will increase from 63% in 2010 to 
71% in 2050.1 Because of many reasons, such as the variation 
of lifestyles and genetic resources, there is huge diversity in the 
prevalence of dementia between regions and countries.1 
Iran has experienced a rapid reduction in population growth over 
the recent decade. This caused a quick increase in the aged popu-
lation.11 Despite the WHO recommendation to countries for con-
ducting studies to detect the prevalence of dementia at national 
levels,20 the prevalence of dementia has not been investigated in a 
national survey in Iran yet. Moreover, there are very sparse studies 
which have addressed the prevalence of dementia at the subna-
tional levels. Naghavi’s study estimated the burden of dementia 
????????????????????????????????????????????????????????????????-
onstrated that dementia accounts for about 0.445% of total calcu-
lated DALYs in Iran.21 However, in the GBD study, the number of 
people with dementia was estimated at about 309,000 individuals 
and its burden was equal to 0.42% of the DALYs in Iran.3 This 
discrepancy in burden of dementia between two studies may be 
due to the differences of data sources used for estimation of de-
mentia burden or is because of various models which were used 
in these studies.
We expect to have wide variation in the prevalence of dementia 
in different regions of Iran because of the wide variety of risk 
factors (e.g., difference in the educational levels of older popula-
tion).22
We hope our study will provide more accurate estimation about 
the prevalence and burden of dementia than Naghavi and GBD 
studies because we use multiple sources of data and newer math-
ematical and statistical models. In the previous study on the bur-
den of diseases in 2003, data were extracted from six provinces of 
Iran,21 while we will use the data of drug selling and prescription 
from all 31 provinces of Iran. 
Furthermore, over the recent 10 years from 2003, when the pre-
vious study on the burden of disease was conducted in Iran, the 
prevalence of dementia in Iran is expected to have increased be-
cause of the increasing of the older people percent.11 Our study 
will provide new information about the prevalence and burden 
of dementia and their trends over 24 years from 1990 to 2013 at 
both national and sub-national levels. The data about the preva-
lence of dementia and its trend at provincial level could determine 
an inequality about dementia prevalence between the regions and 
provinces of Iran. This information helps researchers and health 
providers to detect the risk factors of dementia in each region and 
consequently, design interventions to reduce the inequity between 
provinces. The prevalence that will be reported by our study is 
????????????????????????????????????????????????????????????????
needed to provide care for the patients with dementia at the pro-
vincial level, as well.
In addition, these data could be used as baseline data for future 
????????????? ?????????????????????????????????????????????????????
intervention in health system, which will be initiated by the Min-
ister of Health in 2014.23 
We will use drug consumption as a proxy for estimation of the 
prevalence of dementia since we do not have enough popula-
tion-based cross-sectional data in Iran. This method could have 
compatible accuracy with traditional cross-sectional studies for 
estimating the prevalence of diseases, particularly for chronic 
???????????????????????????????????????????????????????????????
drugs.24–26 
There are several sources of uncertainty in our study. The most 
important one is the utilization of some proxies for estimation of 
???????????????? ??????????????????????????????????????????????????
drug sales could lead to some biases which neglecting them may 
cause a biased estimation of prevalence. One of these biases is that 
patients with various severity of disease may not consume similar 
??????????????????????????????????????????????????????????????????
be discontinued in patients with severe dementia because of inef-
???????????????????????????????????????????????????????????????????
because patients may not consume the recommended doses. As 
a result, a given drugs may not be used by the patients accord-
ing to the prescribed doses. To reduce these biases, we have paid 
special attention to the likely problems during study design. The 
number of patients with severe dementia will be extracted from 
???????????????????????????????????????????????????????????????????
data. These sources of data could give us a relatively good esti-
mation of the prevalence of severe dementia. Misdiagnosis and 
drug adherence rate is our other big challenges that we cannot deal 
with properly. As mentioned before, we will try to extract the drug 
adherence rate from documents of Iranian Alzheimer’s associa-
tion. However, this data may not be generalizable to all patients. 
Another issue to consider is that in our study the proportion of 
patients in age-sex groups in the population under the coverage of 
insurances will be generalized to the general population. Although 
the population with health insurance coverage may show higher 
demand for health services such as referring to doctors and get-
ting treatment, we do not have any reason that the proportions of 
patients in each age group with insurance are different from the 
other population. Moreover, these two health insurance organiza-
tions (whose prescription we will use) have an extended coverage 
and cover more than 60% of the Iranian population.27 Some of 
uncertainty could be caused by low validation of data source; e.g., 
data on drug sales may not be precise enough, or data which will 
?????????????????????????? ????????????????????????????????????-
terval because of the method of sampling and small sample sizes 
or methods of diagnosis of dementia.
Another source of uncertainty will be due to the models which 
will be applied in our study. Each model has a level of inherent 
uncertainty. We will try to reduce this source of uncertainty by 
?????????????????? ?????????????????????????
In conclusion, it seems reasonable to conduct a study for estima-
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tion of prevalence and burden of dementia in Iran at national and 
subnational levels. Despite the fact that the data used in our study 
will face some drawbacks, applying multiple sources of data and 
some new statistical models can relatively solve them and there-
fore provide good information about the prevalence and burden of 
dementia with an acceptable level of uncertainty for policymakers 
and researchers.  
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